NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibitor and exercise performance enhancement products. The company was formerly known as PNC MetaPharm Co., Ltd. and changed its name to NovMetaPharma Co., Ltd. in May 2015. NovMetaPharma Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
तुलना करने के लिए मीट्रिक्स | 229500 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध229500पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −3.3x | −0.5x | |
PEG अनुपात | 0.00 | 0.02 | 0.00 | |
क़ीमत/बुक | 0.0x | 1.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 0.7x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 64.5% | 50.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.3% | 9.1% | अनलॉक करें |